Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2006 | 06-2006 | 03-2006 | 12-2005 | 09-2005 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -37,850 | -26,070 | -12,020 | -96,490 | -26,810 |
| Depreciation Amortization | 4,920 | 3,070 | 1,340 | 4,870 | 4,190 |
| Other Working Capital | -5,750 | -710 | -670 | -2,320 | -3,960 |
| Other Operating Activity | 4,640 | 3,430 | 1,560 | 59,330 | 60 |
| Operating Cash Flow | $-34,040 | $-20,280 | $-9,790 | $-34,610 | $-26,520 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,540 | -810 | -500 | -1,320 | -1,270 |
| Net Acquisitions | -6,460 | -5,810 | -5,590 | 0 | -1,680 |
| Other Investing Activity | 20,170 | 13,130 | 6,300 | 6,720 | 22,190 |
| Investing Cash Flow | $12,170 | $6,510 | $210 | $5,400 | $19,240 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 42,870 | 15,950 | 15,860 | 20,080 | 19,550 |
| Financing Cash Flow | $42,870 | $15,950 | $15,860 | $20,080 | $19,550 |
| Exchange Rate Effect | -440 | -470 | -150 | -50 | 20 |
| Beginning Cash Position | 6,190 | 6,190 | 6,190 | 15,370 | 15,370 |
| End Cash Position | 26,760 | 7,890 | 12,320 | 6,190 | 27,670 |
| Net Cash Flow | $20,560 | $1,690 | $6,120 | $-9,170 | $12,290 |
| Free Cash Flow | |||||
| Operating Cash Flow | -34,040 | -20,280 | -9,790 | -34,610 | -26,520 |
| Free Cash Flow | -34,040 | -20,280 | -9,790 | -34,610 | -26,520 |